<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656551</url>
  </required_header>
  <id_info>
    <org_study_id>MILES-4</org_study_id>
    <secondary_id>2012-000164-25</secondary_id>
    <nct_id>NCT01656551</nct_id>
  </id_info>
  <brief_title>MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer</brief_title>
  <acronym>MILES-4</acronym>
  <official_title>A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to test whether the addition of cisplatin to single agent
      chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with
      non squamous non small cell lung cancer (NSCLC), and to test whether pemetrexed prolongs
      survival as compared to gemcitabine in elderly patients with non squamous NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>factorial design with two comparisons: single agent chemotherapy versus chemotherapy plus cisplatin (Arms A+C versus Arms B + D), and gemcitabine versus pemetrexed (Arms A+B versus Arms C+D)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>evaluated at end of each 3 week cycle of chemotherapy up to 18 weeks</time_frame>
    <description>according to Common Toxicity Criteria for Adverse Events v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life</measure>
    <time_frame>baseline and up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response</measure>
    <time_frame>after 9 and 18 weeks of therapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>identification of patient and lesion specific prognostic factors</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>identification of patient and lesion specific factors predictive of chemotherapy efficacy</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer Stage IIIB</condition>
  <arm_group>
    <arm_group_label>A: Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Pemetrexed + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>A: Gemcitabine</arm_group_label>
    <arm_group_label>B: Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 day 1 every 3 weeks</description>
    <arm_group_label>C: Pemetrexed</arm_group_label>
    <arm_group_label>D: Pemetrexed + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>60 mg/m2 day 1 every 3 weeks</description>
    <arm_group_label>B: Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>D: Pemetrexed + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cytologically or histologically confirmed non-small cell lung cancer.

          -  Non squamous tumor type (including those with a non-specified tumor type).

          -  Metastatic (stage IV, both M1A or M1B) or locally advanced (stage IIIB, with
             metastasis to supraclavicular nodes) according to TNM VII edition.

          -  Both patients at first diagnosis or those with disease recurrence after former surgery
             are eligible.

          -  At least one target or non-target lesion according to RECIST revised version 1.1.

          -  Male or female &gt; or = 70 years of age.

          -  ECOG PS 0 or 1.

          -  Life expectancy &gt; 3 months.

          -  Neutrophils &gt; or = 1500 mm3, platelets &gt; or = 100000 mm3, and haemoglobin &gt; or = 9
             g/dL.

          -  Bilirubin level either normal or &lt; 1.5 x ULN.

          -  AST (SGOT) and ALT (SGPT) &lt; or = 2.5 x ULN (&lt; or = 5 x ULN if liver metastasis are
             present).

          -  Serum creatinine &lt; 1.5 x ULN.

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced
             disease. Prior surgery and/or localised irradiation is permitted. Prior adjuvant
             chemotherapy is permitted if it did not contain gemcitabine and pemetrexed and if at
             least 6 months elapsed from the end of adjuvant chemotherapy.

          -  Any unstable systemic disease (including active infections, significant cardiovascular
             disease or myocardial infarction within the previous year, any significant hepatic,
             renal or metabolic disease), metabolic dysfunction, physical examination finding, or
             clinical laboratory finding that contraindicates the use of study medications or
             render the patient at high risk from treatment complications.

          -  Any other malignancies within 5 years (except for adequately treated carcinoma in situ
             of the cervix or basal or squamous cell skin cancer or surgically resected prostate
             cancer with normal PSA).

          -  Patients with symptomatic brain metastasis or spinal cord compression that has not yet
             been treated with surgery and/or radiation; patients with CNS metastases or spinal
             cord compression previously treated with surgery and/or radiation are eligible if they
             are asymptomatic and do not require steroids (anti-seizure medications are allowed).

          -  Known or suspected hypersensitivity to any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.G. Moscati Hopital, Avellino, Italy, Division of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy; Director Clinical Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples, Italy; Chair of Medical Statistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Di Maio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale San Lazzaro</name>
      <address>
        <city>Alba</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riunit Umberto I-Lancisi-Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Universitaria degli Studi di Roma</name>
      <address>
        <city>Aprilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinal Massaia</name>
      <address>
        <city>Asti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristaria Policlinico Monserrato di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. cardarelli</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 15 Veneto</name>
      <address>
        <city>Camposampiero</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini di Carpi</name>
      <address>
        <city>Carpi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garibalda Nesimadi Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della Madonna della Navicella</name>
      <address>
        <city>Chioggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Faenza</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fabrizio Spaziani</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San Martino IST Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Guastalia</name>
      <address>
        <city>Guastalia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Lugo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS-Meldola</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale L. Sacco Polo Universitario</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 13</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardirelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaleira Ospedali Riuniti Villa Sofia Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs - Crob</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenfratelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia IRCCS - Casa Sollievo Sofferenza</name>
      <address>
        <city>S. Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto-USL di Piacenza</name>
      <address>
        <city>Saliceto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Busto Arsizio</name>
      <address>
        <city>Saronno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Trinità</name>
      <address>
        <city>Sora</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Andrea</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo</name>
      <address>
        <city>Vincenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Viterbo Ospedale Belcolle</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elderly</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

